Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Kavya Keerthana: ASH 2026 Guidelines for Immune Thrombocytopenia
Kavya Keerthana/LinkedIn
Aug 25, 2026, 14:22

Kavya Keerthana: ASH 2026 Guidelines for Immune Thrombocytopenia

Kavya Keerthana, Hematologist at Prime Health, shared a post on LinkedIn about a recent article by Adam Cuker et al., published in Blood Advances, adding:

”ASH 2026 Guidelines for Immune Thrombocytopenia (ITP): What’s Changed?

A major update for the management of adult primary ITP has just been published by the American Society of Hematology.

The 2026 guideline is a focused update of the 2019 recommendations and incorporates evidence from newer clinical trials and therapies.

Key takeaways

1.Corticosteroids alone are no longer the only initial strategy

For adults requiring treatment, ASH 2026 conditionally favors:

  • Corticosteroids and rituximab
  • Corticosteroids and TPO-RA

over corticosteroids alone.

This represents one of the most important shifts from the earlier approach.

2.After corticosteroid failure, move beyond repeated steroid courses

For patients who fail first-line corticosteroids:

  • TPO-RA is strongly recommended
  • Rituximab is conditionally recommended

The choice should be individualized according to bleeding risk, treatment goals, comorbidities, adverse-effect profiles, and-importantly-patient preference.

3.Treatment should be individualized-not platelet-count driven alone

The goal is not simply to normalize the platelet count.

Clinical bleeding, disease duration, treatment toxicity, quality of life and patient priorities remain central to decision-making.

4.TPO-RA switching is supported

5.Splenectomy still has a role-but timing matters

Splenectomy remains an effective treatment option for selected patients, but the guideline emphasizes individualized decision-making and careful consideration of timing, particularly given the possibility of spontaneous remission earlier in the disease course.

The bigger message

The 2026 ASH guideline reflects an important evolution in ITP management:

From ‘How do I increase the platelet count?’ to ‘How do I achieve durable disease control while minimizing treatment burden and improving the patient’s quality of life?’

ITP management is increasingly becoming a shared decision between the Hematologist and patient, rather than a one-size-fits-all platelet-count algorithm.”

Title: American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP

Authors: Adam Cuker, Deirdra R Terrell, Honieh Sowdagar, Donald M Arnold, Sylvain Audia, James B. Bussel, Tomas Jose Gonzalez-Lopez, Rachael F. Grace, Camila Masias, Keith R. McCrae, Mirjana Mitrovic, Cindy E. Neunert, Sandhya Ramanathan Panch, Surbhi Shah, Brenda G Shy, Jessica VandeVelde, Douglas B. Cines, Sara K Vesely

Kavya Keerthana: ASH 2026 Guidelines for Immune Thrombocytopenia

Stay updated with Hemostasis Today.

Adam CukerCorresponding Author bleeding disorders Brenda G Shy Camila Masias Cindy E. Neunert Deirdra R Terrell Donald M. Arnold Douglas B Cines Health Hematology Hemostasis Hemostasis News Hemostasis Today Honieh Sowdagar James B. Bussel Jessica VandeVelde Kavya Keerthana Keith R. McCrae Medicine Mirjana Mitrovic Rachael F. Grace Sandhya Ramanathan Panch Sara K Vesely Surbhi Shah Sylvain Audia Tomas Jose Gonzalez-Lopez
NewsFeed